Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07520916 | The Effect of Mobile-Based Perioperative Education on Urinary Incontinence and Erectile Function After Radical Prostatectomy(MPE-RP) | recruiting | N/A | 78 | Giresun UniversityOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT02706561 | Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery | recruiting | N/A | 224 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 8, 2026 |
| NCT04787744 | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer(VA STARPORT) | recruiting | Phase 2 / Phase 3 | 464 | VA Office of Research and DevelopmentFED | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05469269 | Cleveland African American Prostate Cancer Project | recruiting | N/A | 800 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07516886 | Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy(PPSARP) | recruiting | — | 500 | Lithuanian University of Health SciencesOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06039085 | Microendoscopic EI Sensing for Real-time Intraoperative Surgical Margin Assessment(RARP EI) | recruiting | — | 200 | Ryan J. HalterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07054307 | MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma(MH-Penile-001) | recruiting | Phase 1 | 10 | Jiyan LiuOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06389786 | Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer | recruiting | N/A | 50 | Mayo ClinicOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06651359 | Using a mHealth App to Improve Quality-of-Life Outcomes in Black Prostate Cancer Survivors | recruiting | N/A | 248 | University of OklahomaOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07259213 | A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC(RAD402) | recruiting | Phase 1 / Phase 2 | 73 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05588700 | Impact of a Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor Patients(STARTER) | recruiting | N/A | 236 | Centre Leon BerardOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06193486 | Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC | recruiting | Phase 1 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02016248 | SBRT Boost for Unfavorable Prostate Cancer' | recruiting | N/A | 150 | MemorialCare Health SystemOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT02064673 | Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy | recruiting | Phase 3 | 650 | yair lotanOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05975775 | Outpatient Laparoscopic Radical Prostatectomy(LORP) | recruiting | — | 64 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06244004 | FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial | recruiting | Phase 2 | 125 | Northwestern UniversityOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06280781 | Imperial Prostate 9 - ATLAS (Approaches To Long-Term Active Surveillance)(IP9-ATLAS) | recruiting | N/A | 1,263 | Imperial College LondonOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06389097 | SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization((SEEtoTREAT)) | recruiting | — | 80 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06672926 | NEWPROMRI-PATHWAY - A New Prostate Magnetic Resonance Imaging (MRI) Pathway(NEWPROMRI) | recruiting | — | 1,600 | University Hospitals of North Midlands NHS TrustOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07290270 | Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)(PSMAreal) | recruiting | — | 170 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07500701 | Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer | recruiting | Phase 3 | 270 | Samsung Medical CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07498959 | Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer(TESTIGO) | recruiting | N/A | 160 | Sahlgrenska University HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07073794 | Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer | recruiting | Phase 2 | 38 | Mayo ClinicOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05328505 | Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy for Prostate Cancer(MIDAS-Prostate) | recruiting | N/A | 80 | University Health Network, TorontoOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06638541 | Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions(DESTINATION 2) | recruiting | N/A | 54 | Royal Marsden NHS Foundation TrustOTHER | 2 | Mar 23, 2026 | clinicaltrials |
| NCT06798558 | Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy | recruiting | Phase 2 | 54 | Hackensack Meridian HealthOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07011342 | Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment(SCOUT) | recruiting | N/A | 70 | Hackensack Meridian HealthOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06705686 | Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer(PHAROS) | recruiting | Phase 1 | 40 | TechnoGenesys, Inc.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT03594760 | PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer | recruiting | Phase 3 | 1,000 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06282588 | Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers(THUNDER) | recruiting | Phase 2 / Phase 3 | 493 | Cancer Research AntwerpOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04895839 | Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program(PC-PEP) | recruiting | N/A | 2,130 | Gabriela IlieOTHER | 5 | Mar 18, 2026 | clinicaltrials |
| NCT05435495 | Mechanisms of Resistance to PSMA Radioligand Therapy | recruiting | — | 125 | University of California, San FranciscoOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06422455 | Access to Genetic Testing in Underserved Patients With Cancer | recruiting | N/A | 800 | University of Southern CaliforniaOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05888532 | 64Cu-GRIP B in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 91 | Rahul AggarwalOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07398690 | INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis(INSIGHT-PCa) | recruiting | N/A | 1,432 | In Gab Jeong, MDOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06555588 | Engage Psychosocial Intervention for Cancer Symptoms(Engage) | recruiting | N/A | 190 | Duke UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06966778 | Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial | recruiting | N/A | 135 | National Taiwan University HospitalOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07245745 | Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer | recruiting | N/A | 188 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07422597 | Prostate Risk Or Radiology Assessment Non-inferiority Design, Upfront MRI or Risk Calculator in Men With Suspected Prostate Cancer(PRORAND) | recruiting | N/A | 1,016 | Norwegian University of Science and TechnologyOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06173362 | Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | recruiting | Phase 2 | 75 | University of California, DavisOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06288113 | Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial | recruiting | Phase 2 | 40 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06835218 | PROCARE - PROstate Cancer Real World Evidence Registry(PROCARE) | recruiting | — | 5,000 | UroTrials Company (GmbH)NETWORK | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07460843 | Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis | recruiting | N/A | 592 | Peking University First HospitalOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT03424850 | Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy | recruiting | Phase 1 / Phase 2 | 36 | Washington University School of MedicineOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06437574 | Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer | recruiting | Phase 2 | 140 | Cedars-Sinai Medical CenterOTHER | 1 | Mar 11, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 9, 2026source: clinicaltrials